tetano
Editor, Senior Moderator
PLoS One
. 2021 Jun 29;16(6):e0253889.
doi: 10.1371/journal.pone.0253889. eCollection 2021.
Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity
Nuri Lee[SUP] 1 [/SUP], Seri Jeong[SUP] 1 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The clinical significance of the quantitative value of antibodies in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains mostly unidentified. We investigated the dynamics and clinical implications of the SARS-CoV-2 antibody over time using three automated chemiluminescence immunoassays targeting either nucleocapsids or spikes.
Methods: A total of 126 specimens were collected from 23 patients with confirmed and indeterminate COVID-19 identified by molecular tests. SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).
Results: Three immunoassays showed strong correlations with each other (range of Pearson' s correlation coefficient (r) = 0.700-0.854, P < 0.001). Eleven (8.7%) specimens showed inconsistencies. SARS-CoV-2 IgG showed a statistically significantly higher value in patients with severe disease than that in non-severe disease patients (P < 0.001) and was significantly associated with clinical markers of disease severity.
Conclusion: The quantitative value of the SARS-CoV-2 IgG antibody measured using automated immunoassays is a significant indicator of clinical severity in patients with COVID-19.
. 2021 Jun 29;16(6):e0253889.
doi: 10.1371/journal.pone.0253889. eCollection 2021.
Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity
Nuri Lee[SUP] 1 [/SUP], Seri Jeong[SUP] 1 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP]
Affiliations
- PMID: 34185813
- DOI: 10.1371/journal.pone.0253889
Abstract
Background: The clinical significance of the quantitative value of antibodies in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains mostly unidentified. We investigated the dynamics and clinical implications of the SARS-CoV-2 antibody over time using three automated chemiluminescence immunoassays targeting either nucleocapsids or spikes.
Methods: A total of 126 specimens were collected from 23 patients with confirmed and indeterminate COVID-19 identified by molecular tests. SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).
Results: Three immunoassays showed strong correlations with each other (range of Pearson' s correlation coefficient (r) = 0.700-0.854, P < 0.001). Eleven (8.7%) specimens showed inconsistencies. SARS-CoV-2 IgG showed a statistically significantly higher value in patients with severe disease than that in non-severe disease patients (P < 0.001) and was significantly associated with clinical markers of disease severity.
Conclusion: The quantitative value of the SARS-CoV-2 IgG antibody measured using automated immunoassays is a significant indicator of clinical severity in patients with COVID-19.